Use of disease risk score (DRS)-based confounding adjustment when estimating treatment effects on multiple outcomes is not well studied. We designed an empirical cohort study to compare dabigatran initiators and warfarin initiators with respect to risks of ischemic stroke and major bleeding in 12 sequential monitoring periods (90 days each), using data from the Truven Marketscan database (Truven Health Analytics, Ann Arbor, Michigan). We implemented 2 approaches to combine DRS for multiple outcomes: 1) 1:1 matching on prognostic propensity scores (PPS), created using DRS for bleeding and stroke as independent variables in a propensity score (PS) model; and 2) simultaneous 1:1 matching on DRS for bleeding and stroke using Mahalanobis distance (M-distance), and compared their performance with that of traditional PS matching. M-distance matching appeared to produce more stable results in the early marketing period than both PPS and traditional PS matching; hazard ratios from unadjusted analysis, traditional PS matching, PPS matching, and M-distance matching after 4 periods were 0.72 (95% confidence interval (CI): 0.51, 1.03), 0.61 (95% CI: 0.31, 1.09), 0.55 (95% CI: 0.33, 0.91), and 0.78 (95% CI: 0.45, 1.34), respectively, for stroke and 0.65 (95% CI: 0.53, 0.80), 0.78 (95% CI: 0.60, 1.01), 0.75 (95% CI: 0.59, 0.96), and 0.78 (95% CI: 0.64, 0.95), respectively, for bleeding. In later periods, estimates were similar for traditional PS matching and M-distance matching but suggested potential residual confounding with PPS matching. These results suggest that M-distance matching may be a valid approach for extension of DRS-based confounding adjustments for multiple outcomes of interest. confounding adjustment; disease risk score; observational studies Abbreviations: CI, confidence interval; DRS, disease risk score; M-distance, Mahalanobis distance; PPS, prognostic propensity score; PS, propensity score.
Disease risk scores (DRS), which can summarize multiple outcome risk factors into a single scalar score, are being increasingly utilized in observational studies of drug safety (1) . Conditioning on DRS adjusts for measured confounding by removing associations between covariates and potential outcomes under the control condition (standard-of-care or absent the study drug) to provide a form of balance, which is described as the prognostic balance (2) . DRS-based confounding control may be advantageous when studying the safety of newly marketed medical products or medications for rare diseases because historical data can be used to fit rich DRS models, which can then be used for confounding control in the study sample (3, 4) , while the alternative methods, namely propensity scores (PS) and multivariable outcome regression, require model fitting in the study sample and are therefore infeasible when there is a limited number of exposed patients and outcomes and a relatively large number of confounders (1, 5) .
A number of investigations have found similar performance between DRS-based adjustment and PS-based adjustment in terms of confounding control when the DRS can be modeled accurately (6) (7) (8) . However, one of the often-cited advantages of PS-based adjustment over DRS-based adjustment is that, after PS matching, multiple outcomes can be compared between 2 treatments in a single cohort (3) . In contrast, DRS-based matching would necessitate matching on separate DRS for each outcome, resulting in different cohorts of patients for each outcome of interest. To the extent that the characteristics of the different cohorts vary, the effect estimates for different outcomes may not uniformly apply to a specific target population. Further, in a semiautomated, large-scale monitoring system such as the Food and Drug Administration's Sentinel system (9) , this limitation can severely limit the usefulness of DRS from a practical standpoint because separate queries need to be executed for separate outcomes, which has implications for the timeliness with which critical safety issues can be evaluated. The presence of multiple cohorts also complicates subsequent analysis and reporting. Therefore, identifying novel approaches for combining multiple DRS to facilitate construction of a single matched cohort that can be used to conduct multivariableadjusted evaluations of multiple outcomes is of special interest.
To that end, we conducted an empirical investigation using a case example of dabigatran versus warfarin in an emulated prospective monitoring setting similar to that of the Sentinel system (10) to evaluate approaches of extending DRS-based confounding adjustment to scenarios of multiple outcomes.
METHODS

Study design and data source
We designed a cohort study of patients with atrial fibrillation to compare 2 outcomes of interest-an effectiveness endpoint (a composite endpoint of ischemic stroke (including transient ischemic attack) and systemic embolism) and a safety endpoint (major bleeding)-between initiators of warfarin and initiators of dabigatran (a direct oral anticoagulant). We identified initiation as a prescription dispensation for a drug of interest with no use of either drug in the preceding 6 months and defined this date as the index date. We used commercial insurance claims data from the Truven MarketScan database (Truven Health Analytics, Ann Arbor, Michigan), which contains comprehensive information on patients' use of inpatient and outpatient health-care services, as well as prescription dispensing records, which can be tracked longitudinally.
We first identified a cohort of 39,209 patients between January 1, 2009, and September 30, 2010, who were diagnosed with atrial fibrillation during a 6-month continuous enrollment period preceding the index date. This cohort, which comprised patients who initiated use of warfarin prior to approval of dabigatran (approval date: October 19, 2010), was used as an external historical population to develop DRS models. We opted for this approach of using a historical population to develop DRS (also referred to as the out-of-sample strategy) because it is less prone to overfitting in comparison with the same-sample approach of using only the reference patients (2) . Further, unlike the samesample approach of using the entire cohort to develop the DRS, this approach is not affected by potential contamination of coefficients for risk factors by the treatment effect in the presence of interactions between the treatment and the risk factors (2, 3) .
Next, we emulated a sequential monitoring design similar to that used in some Sentinel assessments (11, 12) , where we monitored outcomes of dabigatran initiation versus warfarin initiation in each of 12 sequential 90-day monitoring periods after the entry of dabigatran into the market (for the period October 2010-October 2013). Patients included in the DRS development sample were ineligible for inclusion in the study cohort used in the sequential monitoring design. In each period, persons who initiated use of dabigatran and warfarin were identified and matched on the basis of each of the summary scores (PS, prognostic PS (PPS), or Mahalanobis distance (M-distance); each approach is described below). The matching was preserved in each monitoring period, and pairs were followed until the most recent period of data availability. An as-treated approach for the outcome assessment was adopted, where patients were censored on the basis of the first occurrence of the following events: not refilling a prescription for their index medication for more than 30 days, switching exposure groups, in-hospital death, disenrollment, or the end of the study period. Our study design is shown in Web Figure 1 (available at https://academic.oup.com/aje).
DRS development
In the historical population of warfarin users (described above), we fitted separate Cox proportional hazards regression models predicting the 2 outcomes of interest: 1) ischemic stroke or systemic embolism and 2) major bleeding (13) . The followup approach adopted in the DRS development model was intention-to-treat, where patients were followed in their treatment group to the earliest of outcome occurrence, plan disenrollment, or 12 months, regardless of exposure status. The intention-to-treat approach has recently shown to be superior to an as-treated approach for DRS development in terms of calibration and confounding control because of the inclusion of a higher number of events, which reduces model overfitting (14) . As risk factors, a total of 57 variables were included in the DRS model for ischemic stroke or systemic embolism, and 54 variables were included in the DRS model for major bleeding, based on clinical judgment. These variables were measured in the 6-month preindex period and included demographic factors, comorbid conditions, and measures of health-care utilization (full list provided in Web Table 1 ). Coefficients and an estimated cumulative baseline hazard obtained from the DRS development models were then used to calculate the 1-year probability of the outcome (i.e., the DRS) for each patient in the study cohort (both dabigatran and warfarin initiators) based on each patient's covariate values.
Discrimination of the DRS models in the study cohort was reported as Harrell's C index (15) . Calibration of the models was evaluated by plotting the predicted 1-year outcome probabilities against the observed 1-year outcome probabilities, where the predicted probability was the average of the DRS in each DRS decile of the study cohort and the observed probability was the Kaplan-Meier failure probability in each decile.
Matching approaches
Prognostic propensity scores. The PPS, as described by Hansen (2) , involves a transformation of the DRS onto the PS scale by including the DRS for multiple outcomes as the sole independent variables in a PS model. We included the DRS for both major bleeding and ischemic stroke or systemic embolism in a logistic regression model predicting initiation of dabigatran versus warfarin and used the resulting predicted probabilities-the PPS-to match dabigatran and warfarin initiators in a 1:1 ratio using a nearest-neighbor approach with a caliper of 0.025 on Am J Epidemiol. 2018;187(11):2439-2448 the probability scale (16) . We included squared terms for both DRS and an interaction term between the 2 scores in the PPS model to allow for nonlinearity and to account for correlation between the scores.
Mahalanobis distance. M-distance is a widely used measure of generalized distance in a multivariate space and has been proposed as an efficient procedure for simultaneous matching on multiple variables (17, 18) . We used DRS for stroke or systemic embolism and bleeding to calculate M-distances between treated (dabigatran) and reference (warfarin) patients as follows:
where Δ = M-distance, x = a row vector consisting of the multivariate measurement (i.e., DRS for stroke or systemic embolism and DRS for bleeding) for a treated observation, m = a row vector consisting of the multivariate measurement (i.e., DRS for stroke or systemic embolism and DRS for bleeding) for a reference observation, C −1 = the inverse covariance matrix of 2 DRS, and (x − m)′ = the transpose of the matrix (x − m).
Dabigatran initiators were then matched in a ratio of 1:1 with warfarin initiators based on the nearest M-distance values. Since M-distances have no unit and are calculated dynamically between each treated unit and all available untreated units, we imposed no caliper restrictions for this approach (17) .
Traditional PS. As a benchmark, we also conducted traditional PS matching, because this method is known to adjust for confounding for multiple outcomes in a single cohort, provided that the risk factors for each outcome are included in the PS model. A logistic regression model was fitted to predict the probability of dabigatran initiation based on the union of the covariates included in the 2 DRS models (listed in Web Table 1 ). This predicted probability was then used to match dabigatran initiators with warfarin initiators in a 1:1 ratio using a nearestneighbor approach with a caliper of 0.025 on the probability scale (16) .
Joint matching on traditional PS and DRS. We implemented joint matching using 2 approaches: 1) 1:1 matching after jointly minimizing M-distances for 3 variables (traditional PS, DRS for stroke or systemic embolism, and DRS for bleeding); and 2) 1:1 matching within traditional PS calipers based on minimum Mdistances for the 2 DRS.
Statistical analysis
We evaluated the performance of the DRS-based methods using the "dry run" approach (2, 19) . Whereas PS-based methods provide "propensity balance," which can be evaluated by assessing covariate balance across exposure groups after matching, DRS-based methods provide "prognostic balance," where balance is achieved between subjects with contrasting potential outcomes under the control condition (standard of care or absent the study drug). "Prognostic balance" does not imply covariate balance and can be evaluated only among patients in the comparator group, where the potential outcome under the control condition is observed. Evaluating prognostic balance only in the comparator group, however, does not necessarily indicate how well prognostic balance is achieved within the entire study population (20) .
To address these challenges, Hansen proposed the "dryrun" analysis to evaluate a DRS model's ability to induce prognostic balance and control for confounding (2, 19) . Briefly, the dry-run analysis involved the following steps. First, a portion of warfarin initiators from the study cohort (i.e., reference group) was sampled as "pseudo-dabigatran" initiators using their PS as the probability of selection in independent Bernoulli trials. Persons not selected as "pseudo-dabigatran" initiators were used as the "pseudo-reference" group. Next, "pseudo-dabigatran" initiators were matched with "pseudo-reference" patients based on the PPS and, separately, M-distance. Cox proportional hazards models were then used to compare hazards in the matched sample. The association between "pseudo-dabigatran" and major bleeding or ischemic stroke or systemic embolism, termed the "pseudo-bias" and presented on the log hazard ratio scale, was the quantity of interest in the "dry run" analyses. Because all patients included in the dry run analysis are exposed to the same drug (warfarin), any association observed between "pseudo-dabigatran" and outcome can be attributed to residual confounding. The success of each approach was evaluated on the basis of its ability to retrieve unconfounded null results in the dry run analysis (i.e., pseudo-bias values of 0). We repeated the dry run analyses 1,000 times to provide a distribution of the pseudo-bias for each outcome with each method. For the traditional PS matching, performance was evaluated using standardized differences in mean values or prevalences of the confounders between the dabigatran and warfarin patients after matching.
For each of the matching approaches, Cox proportional hazards models were used to estimate hazard ratios and nominal 95% confidence intervals comparing dabigatran initiators with warfarin initiators for both outcomes cumulatively after the addition of each quarter of data, for a total of 12 quarters. The precision of estimates for all matching approaches is reported using confidence limit ratios (21) . All analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina). Programming codes used in this study for DRS calculations are available on our website (22) .
Sensitivity analysis
In the primary analysis, we did not consider in-hospital mortality as a competing event. To evaluate the robustness of our primary analysis, we conducted a sensitivity analysis wherein we used subdistribution hazard models in the historical cohort of warfarin patients to estimate DRS for both outcomes in the presence of competing risk of in-hospital death. We then used cause-specific hazard models in the concurrent cohort to provide hazard ratios for the association between dabigatran use and risk of stroke or systemic embolism and bleeding after considering in-hospital death as a competing event (23) .
RESULTS
DRS development models
In the historical cohort of 39,209 warfarin initiators, we developed DRS models for ischemic stroke or systemic embolism and bleeding based on 514 and 1,934 observed events, respectively. In the study cohort, Harrell's C indices were 0.68 for the stroke or systemic embolism outcome and 0.63 for bleeding. Calibration plots suggested potential miscalibration in higher risk strata, especially for the bleeding outcome. In lower risk strata, the models were well calibrated for both outcomes (Figure 1 ).
Study cohort
A total of 79,265 patients were included in the study cohort, including 56,456 warfarin initiators and 22,809 dabigatran initiators. The warfarin initiator group was older (average age, 71 years vs. 67 years) and had higher prevalence of comorbid conditions, including preexisting coronary artery disease, diabetes, and renal insufficiency, than dabigatran initiators ( Table 1) .
Performance of the matching approaches
Results from the "dry run" analyses are presented in Figure 2 . The pseudo-bias values for crude models for both of the outcomes were −0.17, suggesting that the sampling procedure was successful in introducing confounding of a substantial magnitude in the expected direction (downward and away from the null). After matching on the PPS and M-distance, this confounding was largely removed, as reflected by average pseudo-bias values close to the null value for both procedures. However, in a larger proportion of dry run procedures for both of the outcomes, PPS matching resulted in negative pseudo-bias values compared with M-distance matching, suggesting a higher potential for residual confounding with the PPS approach versus the M-distance approach. The median values were −0.03 (2.5th-97.5th percentile range: −0.30 to 0.24) and 0.03 (2.5th-97.5th percentile range: −0.27 to 0.32) for ischemic stroke or systemic embolism and −0.03 (2.5th-97.5th percentile range: −0.18 to 0.12) and −0.02 (2.5th-97.5th percentile range: −0.15 to 0.11) for major bleeding in the PPS-matched and M-distance-matched approaches, respectively.
The traditional PS matching achieved excellent balance in the distribution of all included variables (average absolute standardized difference, 0.01; see Web Table 2 ). Web Figures 2-4 show distributional overlap in PS and both DRS between warfarin and dabigatran groups over each monitoring period.
Estimates from the empirical evaluation
The unadjusted analysis suggested lower risk of stroke or systemic embolism in dabigatran initiators versus warfarin initiators ( Figure 3 ). During early monitoring periods, all matching approaches resulted in estimates with wide confidence intervals; however, M-distance matching based on 2 DRS appeared to result in comparatively more stable estimates that were closer to the null. The unadjusted analysis suggested lower risk of bleeding in dabigatran initiators versus warfarin initiators (Figure 4) . Overall, the pattern of more stable estimates for M-distance matching compared with traditional PS and PPS matching during early monitoring periods was also observed for bleeding. However, because major bleeding occurred more frequently than stroke or systemic embolism, estimates stabilized quickly for all approaches, and after 12 periods, hazard ratios for traditional PS matching, PPS matching, M-distance matching based on 2 DRS, M-distance matching based on traditional PS and 2 DRS, and M-distance matching based on 2 DRS within a PS caliper were 0. Overall, the precision was lower for traditional PS matching and M-distance matching on 2 DRS within a PS caliper than for other methods during early monitoring periods (Web Figure 5) . Deciles were created on the basis of predicted probabilities (i.e., disease risk scores), and the average of predicted probabilities was plotted for each decile. The observed probability was the average KaplanMeier failure probability in each decile. A) Calibration plot for the stroke or systemic embolism outcome; B) calibration plot for the bleeding outcome. However, the precision of all approaches was nearly equivalent in later monitoring periods.
Sensitivity analysis
The discrimination of the DRS model developed from subdistribution hazard models which accounted for the competing risk of in-hospital death was identical to the discrimination noted in the primary model. The cause-specific hazard ratios for stroke or systemic embolism and bleeding risks were also very similar to those from the primary analysis (Web Figures 6 and 7) .
DISCUSSION
In this empirical evaluation of different approaches for extending DRS-based confounding adjustment when evaluating multiple outcomes, we noted that M-distance matching on multiple DRS produced estimates that were close to those from traditional PS matching, but PPS matching resulted in estimates with potential residual confounding compared with traditional PS matching. Further, M-distance matching on multiple DRS appeared to produce more stable results in the very early marketing period than both PPS and traditional PS matching, as demonstrated by higher precision and proximity to the estimates from later periods. Even during later marketing periods, where traditional PS-based approaches are thought to have an edge, M-distance matching on multiple DRS demonstrated similar performance.
Our observation that DRS-based approaches can be successfully extended for confounding control when evaluating multiple outcomes in a single matched cohort has direct implications for pharmacoepidemiology practice. There are certain settings in which DRS approaches may be preferred over PS approaches due to challenges in building robust PS models because of a limited number of exposed patients, as in monitoring of newly marketed medications in FDA's Sentinel system. In these settings, it may be feasible to streamline DRS-based confounding adjustment for multiple outcomes using the approaches evaluated here. Several features of M-distance matching on multiple DRS may explain its apparent superior performance over the PPS approach. First, unlike the PPS approach, which requires modeling of the association between DRS and treatment assignment, M-distance matching is nonparametric (17) and requires no assumptions to be made regarding the association between the DRS and treatment selection. While both M-distance matching and PPS require correct specification of the DRS models, PPS also requires correct specification of the functional form between the DRS and treatment in the secondstage PS model. Second, M-distance takes into account the correlation among multiple DRS through a covariance matrix. This property may also adversely affect the performance of Mdistance matching when a large number of factors are considered for matching. However, the performance of M-distance matching was found to be robust for up to 5 variables in a previous simulation study (24) . Therefore, we expect that this is not a major limitation, as many investigations involve fewer than 5 outcomes.
In this empirical example, we observed no substantial gains in precision or bias adjustment with the approaches that combined 2 DRS with the traditional PS over MD matching on 2 DRS (see Figures 3 and 4 and Web Figure 5 ). In a simulation study, Leacy and Stuart (18) also reported that matching on DRS alone performs identically to the joint DRS and PS matching approaches when the DRS model is correctly specified. Future research should focus on identifying specific scenarios where matching approaches combining both DRS and PS may provide practical advantages over simply matching on M-distances on multiple DRS.
DRS-based confounding adjustments have certain challenges that may limit their use in practical applications (1). First and foremost, out-of-sample DRS development is preferred to same-sample development to avoid issues related to overfitting and contamination of coefficients by the treatment effect in case of interactions between treatment and risk factors, but out-of-sample estimation requires an appropriate and large external population, such as a recent historical cohort of comparator drug users (2). Second, DRS-based adjustments are not particularly useful when outcomes are rare even in the development cohort. Despite these well-recognized limitations, DRSbased adjustment approaches are appealing in certain applications. In the case of early monitoring of medication effects in active surveillance programs such as Sentinel, DRS models developed using historical data can be used to directly calculate DRS without the need to refit models in each monitoring period, whereas models need to be refitted to calculate PS with addition of new data for each monitoring period. Results from this study, which demonstrate that an often cited limitation of DRS-based adjustments concerning multiple outcomes of interest can be effectively addressed, open up the possibility of extending use of DRS in studies in which investigators want to simultaneously evaluate multiple outcomes.
The comparative risk of ischemic stroke or systemic embolism and major bleeding between dabigatran and warfarin users has been studied previously in clinical trials and observational studies. In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Study, Connolly et al. (25) found a lower risk of ischemic stroke or systemic embolism in patients randomized to receipt of dabigatran versus warfarin (relative risk = 0.66, 95% CI: 0.53, 0.82) and no difference in the risk of major bleeding (relative risk = 0.93, 95% CI: 0.81, 1.07). In an observational study of Medicare enrollees with atrial fibrillation, Graham et al. (26) reported a hazard ratio of 0.80 (95% CI: 0.67, 0.96) for the risk of ischemic stroke and a hazard ratio of 0.97 (95% CI: 0.88, 1.07) for the risk of major bleeding for dabigatran initiators versus warfarin initiators. In a recent observational study, Go et al. (27) noted no significant differences in the risk of ischemic stroke (hazard ratio = 0.92, 95% CI: 0.65, 1.28) or major extracranial bleeding (hazard ratio = 0.89, 95% CI: 0.72, 1.09) between initiators of dabigatran and warfarin. Thus, results from previously published studies differ somewhat from each other and from the estimates reported in our study. One potential reason for observed differences in estimates across these studies could be differences in the baseline characteristics of patients included, which can yield apparently different average treatment effects across studies in the presence of treatment effect heterogeneity (28) .
There were some limitations of this study that deserve mention. We only evaluated the performance of different approaches in 1 empirical example, which may limit the generalizability of the results. However, with a relatively widely used medication, such as dabigatran, we would expect the PS-based methods to perform especially well. Results from this study noting that Mdistance matching performed similarly to traditional PS matching in this example are encouraging. While we emulated a Sentinellike surveillance protocol, it is noteworthy that we used just 1 database and did not conduct this study in a distributed data network. However, addition of more than 1 database from a distributed data network is unlikely to affect the performance of methods described in this investigation. Indeed, use of DRSbased adjustment may be advantageous in such settings because DRS models developed from a historical cohort in the largest database could potentially be used to calculate DRS in smaller data partners without the need to refit DRS models, as long as all important interactions between risk factors are modeled while developing the DRS. In contrast, PS models may not be readily transportable because treatment determinants probably vary across health-care systems. Next, our DRS model for bleeding did not calibrate particularly well in the study cohort ( Figure 1 ) and had limited discrimination, highlighting the difficulty associated with building DRS models from insurance claims data that do not contain information on certain clinical factors, leading to the possibility of residual confounding. Additionally, a large amount of missing data in the DRS development cohort may lead to inaccurate modeling of the risk factoroutcome association and could potentially result in suboptimal performance of this method in terms of confounding control. Nevertheless, a lack of information regarding important risk factors that may be confounders would result in residual confounding for both DRS-and PS-based adjustment strategies. Finally, since we used an empirical example, we had no knowledge of the true parameter estimates for the effect of dabigatran on the risk of stroke or systemic embolism or bleeding, which makes the comparison across the 3 approaches challenging.
In conclusion, we observed that simultaneous M-distance matching using multiple DRS led to similar confounding adjustment as a traditional PS-based approach in the analysis of multiple outcomes. These findings provide support for a novel strategy to address one of the most commonly noted limitations of DRS-based adjustment approaches. This work was supported through the Sentinel Coordinating Center, which is funded by the Food and Drug Administration (FDA) through the Department of Health and Human Services (contract HHSF223200910006I). S.V.W. was supported by grant R00HS022193 from the Agency for Healthcare Research and Quality.
The Sentinel system is sponsored by the FDA to proactively monitor the safety of FDA-regulated medical products and complements other existing FDA safety surveillance capabilities. The Sentinel system is one piece of the FDA's Sentinel Initiative, a long-term, multifaceted effort to develop a national electronic system for active safety surveillance of FDA-regulated medical products. Sentinel collaborators include data partners and academic partners that provide access to health-care data and ongoing scientific, technical, methodological, and organizational expertise.
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